Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT02997228	TitleCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study	Phase Phase 3	Date Added 2016-12-20	Location Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States	Prior IO Allowed No	CRC-directed Yes	Status Suspended	Drugs Atezolizumab, fluorouracil, Leucovorin, oxaliplatin	Tags MSI-H/ MMRd
NCT ID NCT02988960	TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors	Phase Phase 1	Date Added 2016-12-12	Location California, United States Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs ABBV-181, ABBV-927, Opdivo	Tags MSS/ MMRp
NCT ID NCT02925234	TitleThe Drug Rediscovery Protocol (DRUP Trial)	Phase Phase 2	Date Added 2016-10-05	Location Netherlands	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02888743	TitleDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	Phase Phase 2	Date Added 2016-09-05	Location Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs durvalumab, Tremelimumab	Tags MSS/ MMRp
NCT ID NCT02886585	TitlePembrolizumab In Central Nervous System Metastases	Phase Phase 2	Date Added 2016-09-01	Location Massachusetts, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT02869217	TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase Phase 1	Date Added 2016-08-16	Location Canada	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Cyclophosphamide, Fludarabine, TBI-1301	Tags MSS/ MMRp
NCT ID NCT02864485	TitleLiving Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases	Phase Not Applicable	Date Added 2016-08-12	Location Canada	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02856425	TitleTrial Of Pembrolizumab And Nintedanib	Phase Phase 1	Date Added 2016-08-04	Location France	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef	Tags MSS/ MMRp
NCT ID NCT02693535	TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Phase Phase 2	Date Added 2016-02-26	Location Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02675946	TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)	Phase Phase 1	Date Added 2016-02-05	Location California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda	Tags MSS/ MMRp

Showing 271 to 280 of 299 entries